Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2017

Open Access 01-12-2017 | Research article

Centralising and optimising decentralised stroke care systems: a simulation study on short-term costs and effects

Authors: Maarten M. H. Lahr, Durk-Jouke van der Zee, Gert-Jan Luijckx, Patrick C. A. J. Vroomen, Erik Buskens

Published in: BMC Medical Research Methodology | Issue 1/2017

Login to get access

Abstract

Background

Centralisation of thrombolysis may offer substantial benefits. The aim of this study was to assess short term costs and effects of centralisation of thrombolysis and optimised care in a decentralised system.

Methods

Using simulation modelling, three scenarios to improve decentralised settings in the North of Netherlands were compared from the perspective of the policy maker and compared to current decentralised care: (1) improving stroke care at nine separate hospitals, (2) centralising and improving thrombolysis treatment to four, and (3) two hospitals. Outcomes were annual mean and incremental costs per patient up to the treatment with thrombolysis, incremental cost-effectiveness ratio (iCER) per 1% increase in thrombolysis rate, and the proportion treated with thrombolysis.

Results

Compared to current decentralised care, improving stroke care at individual community hospitals led to mean annual costs per patient of $US 1,834 (95% CI, 1,823–1,843) whereas centralising to four and two hospitals led to $US 1,462 (95% CI, 1,451–1,473) and $US 1,317 (95% CI, 1,306–1,328), respectively (P < 0.001). The iCER of improving community hospitals was $US 113 (95% CI, 91–150) and $US 71 (95% CI, 59–94), $US 56 (95% CI, 44–74) when centralising to four and two hospitals, respectively. Thrombolysis rates decreased from 22.4 to 21.8% and 21.2% (P = 0.120 and P = 0.001) in case of increasing centralisation.

Conclusions

Centralising thrombolysis substantially lowers mean annual costs per patient compared to raising stroke care at community hospitals simultaneously. Small, but negative effects on thrombolysis rates may be expected.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lahr MM, Luijckx GJ, Vroomen PC, van der Zee DJ, Buskens E. Proportion of patients treated with thrombolysis in a centralised versus a decentralised acute stroke care setting. Stroke. 2012;43:1336–40.CrossRefPubMed Lahr MM, Luijckx GJ, Vroomen PC, van der Zee DJ, Buskens E. Proportion of patients treated with thrombolysis in a centralised versus a decentralised acute stroke care setting. Stroke. 2012;43:1336–40.CrossRefPubMed
2.
go back to reference Hunter RM, Davie C, Rudd A, Thompson A, Walker H, Thomson N, et al. Impact on clinical and cost outcomes of a centralised approach to acute stroke care in London: a comparative effectiveness before and after model. PLoS One. 2013;8:e70420.CrossRefPubMedPubMedCentral Hunter RM, Davie C, Rudd A, Thompson A, Walker H, Thomson N, et al. Impact on clinical and cost outcomes of a centralised approach to acute stroke care in London: a comparative effectiveness before and after model. PLoS One. 2013;8:e70420.CrossRefPubMedPubMedCentral
3.
go back to reference Meretoja A, Roine RO, Kaste M, Linna M, Roine S, Juntunen M, et al. Effectiveness of primary and comprehensive stroke centres: PERFECT stroke: a nationwide observational study from Finland. Stroke. 2010;41:1102–7.CrossRefPubMed Meretoja A, Roine RO, Kaste M, Linna M, Roine S, Juntunen M, et al. Effectiveness of primary and comprehensive stroke centres: PERFECT stroke: a nationwide observational study from Finland. Stroke. 2010;41:1102–7.CrossRefPubMed
4.
go back to reference Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centres for acute stroke care. Stroke. 2012;43:1617–23.CrossRefPubMed Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centres for acute stroke care. Stroke. 2012;43:1617–23.CrossRefPubMed
5.
go back to reference Dirks M, Baeten SA, Dippel DW, van Exel NJ, van Wijngaarden JD, Huijsman R, et al. Real-life costs and effects of an implementation program to increase thrombolysis in stroke. Neurology. 2012;79:508–14.CrossRefPubMed Dirks M, Baeten SA, Dippel DW, van Exel NJ, van Wijngaarden JD, Huijsman R, et al. Real-life costs and effects of an implementation program to increase thrombolysis in stroke. Neurology. 2012;79:508–14.CrossRefPubMed
6.
go back to reference Verweij A, Sanderse C, Beer de J. Zijn er in nederland verschillen naar regio? in: Volksgezondheid toekomst verkenning, nationaal kompas volksgezondheid. bilthoven: RIVM. 2011. Available at: http://www.nationaalkompas.nl>. nationaal kompas Volksgezondheid\Bevolking. Accessed 8 Aug 2016. Verweij A, Sanderse C, Beer de J. Zijn er in nederland verschillen naar regio? in: Volksgezondheid toekomst verkenning, nationaal kompas volksgezondheid. bilthoven: RIVM. 2011. Available at: http://​www.​nationaalkompas.​nl>. nationaal kompas Volksgezondheid\Bevolking. Accessed 8 Aug 2016.
7.
go back to reference Gumbinger C, Reuter B, Stock C, Sauer T, Wiethölter H, Bruder I, et al. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ. 2014;348:g3429.CrossRefPubMedPubMedCentral Gumbinger C, Reuter B, Stock C, Sauer T, Wiethölter H, Bruder I, et al. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ. 2014;348:g3429.CrossRefPubMedPubMedCentral
8.
go back to reference Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. Lancet. 2007;369:275–82.CrossRefPubMed Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. Lancet. 2007;369:275–82.CrossRefPubMed
9.
go back to reference Ambulancezorg Nederland. Landelijke standaard meldkamer ambulancezorg (LSMA-2). 2011. Accessed 8 Aug 2016. Ambulancezorg Nederland. Landelijke standaard meldkamer ambulancezorg (LSMA-2). 2011. Accessed 8 Aug 2016.
10.
go back to reference Aries E, Bosker H, van Boven J, et al. Landelijk protocol ambulancezorg. herziene versie 7.2. 2011. Accessed 8 Aug 2016. Aries E, Bosker H, van Boven J, et al. Landelijk protocol ambulancezorg. herziene versie 7.2. 2011. Accessed 8 Aug 2016.
12.
go back to reference Lahr MM, van der Zee DJ, Luijckx GJ, Vroomen PC, Buskens E. A simulation based approach for improving utilisation of thrombolysisin acute brain infarction. Med Care. 2013;51:1101–5.CrossRefPubMed Lahr MM, van der Zee DJ, Luijckx GJ, Vroomen PC, Buskens E. A simulation based approach for improving utilisation of thrombolysisin acute brain infarction. Med Care. 2013;51:1101–5.CrossRefPubMed
13.
go back to reference Law AM, Kelton WD. Simulation modelling and analysis. 4th ed. New York: McGraw-Hill; 2007. Law AM, Kelton WD. Simulation modelling and analysis. 4th ed. New York: McGraw-Hill; 2007.
14.
go back to reference Law AM. ExpertFit Version 8 User’s Guide. Tuscon: Averill M. Law & Associates; 2011. Law AM. ExpertFit Version 8 User’s Guide. Tuscon: Averill M. Law & Associates; 2011.
17.
go back to reference Nallamothu BK, Bates ER, Wang Y, Bradley EH, Krumholz HM. Driving times and distances to hospitals with percutaneous coronary intervention in the United States: implications for prehospital triage of patients with ST-elevation myocardial infarction. Circulation. 2006;113:1189–95.CrossRefPubMed Nallamothu BK, Bates ER, Wang Y, Bradley EH, Krumholz HM. Driving times and distances to hospitals with percutaneous coronary intervention in the United States: implications for prehospital triage of patients with ST-elevation myocardial infarction. Circulation. 2006;113:1189–95.CrossRefPubMed
18.
go back to reference Nedeltchev K, Arnold M, Brekenfeld C, Isenegger J, Remonda L, Schroth G, et al. Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke. 2003;34:1230–4.CrossRefPubMed Nedeltchev K, Arnold M, Brekenfeld C, Isenegger J, Remonda L, Schroth G, et al. Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke. 2003;34:1230–4.CrossRefPubMed
19.
go back to reference Meretoja A, Keshtkaran M, Saver JL, Tatlisumak T, Parsons MW, Kaste M, et al. Stroke thrombolysis: save a minute, save a day. Stroke. 2014;45:1053–8.CrossRefPubMed Meretoja A, Keshtkaran M, Saver JL, Tatlisumak T, Parsons MW, Kaste M, et al. Stroke thrombolysis: save a minute, save a day. Stroke. 2014;45:1053–8.CrossRefPubMed
20.
go back to reference Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–703.CrossRefPubMed Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–703.CrossRefPubMed
21.
go back to reference Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischaemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750–8.CrossRefPubMed Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischaemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750–8.CrossRefPubMed
22.
go back to reference Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.CrossRefPubMed Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.CrossRefPubMed
23.
go back to reference Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957;2:200–15.PubMed Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957;2:200–15.PubMed
24.
go back to reference Drummond M, Sculpher MJ, Torrance GW, Stoddart GL, O’Brien GJ. Methods for the economical evaluation of health care programs. 3rd ed. New York: Oxford University Press; 2005. Drummond M, Sculpher MJ, Torrance GW, Stoddart GL, O’Brien GJ. Methods for the economical evaluation of health care programs. 3rd ed. New York: Oxford University Press; 2005.
25.
go back to reference Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L. Update of the dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28:152–8.CrossRefPubMed Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L. Update of the dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28:152–8.CrossRefPubMed
26.
go back to reference Demaerschalk BM, Yip TR. Economic benefit of increasing utilisation of intravenous tissue plasminogen activator for acute ischaemic stroke in the United States. Stroke. 2005;36:2500–3.CrossRefPubMed Demaerschalk BM, Yip TR. Economic benefit of increasing utilisation of intravenous tissue plasminogen activator for acute ischaemic stroke in the United States. Stroke. 2005;36:2500–3.CrossRefPubMed
27.
go back to reference Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79:306–13.CrossRefPubMed Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79:306–13.CrossRefPubMed
28.
go back to reference Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, Truesdale M, Davis SM, Campbell BC. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81(12):1071–6.CrossRefPubMed Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, Truesdale M, Davis SM, Campbell BC. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81(12):1071–6.CrossRefPubMed
29.
go back to reference Branas CC, MacKenzie EJ, Williams JC, Schwab CW, Teter HM, Flanigan MC, et al. Access to trauma centres in the United States. JAMA. 2005;293:2626–33.CrossRefPubMed Branas CC, MacKenzie EJ, Williams JC, Schwab CW, Teter HM, Flanigan MC, et al. Access to trauma centres in the United States. JAMA. 2005;293:2626–33.CrossRefPubMed
30.
go back to reference Morris S, Hunter RM, Ramsay AI, Boaden R, McKevitt C, Perry C, et al. Impact of centralising acute stroke services in English metropolitan areas on mortality and length of hospital stay: difference-in-differences analysis. BMJ. 2014;349:g4757.CrossRefPubMedPubMedCentral Morris S, Hunter RM, Ramsay AI, Boaden R, McKevitt C, Perry C, et al. Impact of centralising acute stroke services in English metropolitan areas on mortality and length of hospital stay: difference-in-differences analysis. BMJ. 2014;349:g4757.CrossRefPubMedPubMedCentral
31.
go back to reference van Zorgverzekeraars C. Handleiding voor kostenonderzoek [Dutch]. 2015. Available at: www.cvz.nl. Accessed 8 Aug 2016. van Zorgverzekeraars C. Handleiding voor kostenonderzoek [Dutch]. 2015. Available at: www.​cvz.​nl. Accessed 8 Aug 2016.
32.
go back to reference Claes N, Moeremans K, Frank B, Jef A, Jos V, Herman VL, et al. Estimating the cost-effectiveness of quality-improving interventions in oral anticoagulation management within general practice. Value Health. 2006;9:369–76.CrossRefPubMed Claes N, Moeremans K, Frank B, Jef A, Jos V, Herman VL, et al. Estimating the cost-effectiveness of quality-improving interventions in oral anticoagulation management within general practice. Value Health. 2006;9:369–76.CrossRefPubMed
33.
go back to reference Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, et al. Revised and updated recommendations for the establishment of primary stroke centres: a summary statement from the brain attack coalition. Stroke. 2011;42:2651–65.CrossRefPubMed Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, et al. Revised and updated recommendations for the establishment of primary stroke centres: a summary statement from the brain attack coalition. Stroke. 2011;42:2651–65.CrossRefPubMed
Metadata
Title
Centralising and optimising decentralised stroke care systems: a simulation study on short-term costs and effects
Authors
Maarten M. H. Lahr
Durk-Jouke van der Zee
Gert-Jan Luijckx
Patrick C. A. J. Vroomen
Erik Buskens
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2017
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-016-0275-3

Other articles of this Issue 1/2017

BMC Medical Research Methodology 1/2017 Go to the issue